Who Supplies Irbesartan to India from GERMANY

Importing finished pharmaceutical formulations containing Irbesartan into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, approval under Rule 122E is necessary before importation. Applications for registration and import licenses must be submitted to the Drugs Controller General (India) at CDSCO. The registration process involves submitting detailed product information, manufacturing details, and quality control data. The timeline for import drug registration varies but typically ranges from several months to over a year, depending on the complexity of the product and the completeness of the application. For formulations under HS Code 30049079, specific requirements include comprehensive stability data, quality control measures, and compliance with Indian Pharmacopoeia standards.

Imported finished pharmaceutical formulations containing Irbesartan must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, with each batch requiring a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is conducted to verify compliance with regulatory standards. If a batch fails quality testing, it may be subject to rejection, destruction, or re-export, depending on the severity of the non-compliance.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the importation of pharmaceutical products to enhance drug safety and efficacy. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Germany have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for German manufacturers.

India imports finished Irbesartan formulations to meet the demand for branded and patented products not manufactured domestically. Specific dosage forms, such as extended-release tablets, may not be produced locally, necessitating imports. Despite a robust domestic pharmaceutical industry, certain specialized formulations are sourced from abroad to fulfill market needs. The market size for Irbesartan formulations in India is substantial, with a growing patient population requiring antihypertensive treatments.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049079 is 10%. An additional Social Welfare Surcharge (SWS) of 10% on BCD is applicable. Integrated Goods and Services Tax (IGST) is levied as per prevailing rates, which vary based on the product classification and applicable notifications. There are no specific exemptions or concessional duties for products originating from Germany under this HS Code. The total landed duty percentage combines BCD, SWS, and IGST, impacting the final cost of imported goods.

India sources finished Irbesartan formulations from Germany due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms not produced domestically. Germany's share in India's Irbesartan import market is significant, reflecting its competitive advantage in quality and innovation. Other suppliers, such as China and the United States, also participate in this market, but Germany's reputation for high-quality pharmaceutical products positions it favorably.

India imports finished Irbesartan formulations from Germany due to the availability of patented formulations, specialized dosage forms, and technology-licensed products that are not manufactured domestically. Germany's advanced pharmaceutical manufacturing capabilities and adherence to international quality standards make it a preferred source for these formulations.

Compared to other origins like China, the European Union, and the United States, Germany offers advantages in terms of product quality, regulatory compliance, and reliability. While other countries may offer competitive pricing, Germany's reputation for high-quality pharmaceutical products and adherence to stringent regulatory standards provide a unique advantage in the Indian market.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to quality issues and regulatory recalls, emphasizing the need for robust risk management strategies.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate single-source dependency.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with demand forecasts to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with CDSCO, including submission of Form 40/41.
3. 3Drug Import License: Secure a license for importing drugs into India.
4. 4No Objection Certificate (NOC): Obtain NOC from relevant authorities if required.
5. 5Customs Broker: Engage a licensed customs house agent for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049079 to confirm